B9E0623C-E3AC-4B2B-983E-C2246AD0DB00
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 75.19710906701708
- age_years
- 58
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.588
- MYC_TARGETS_V1+0.488
- OXIDATIVE_PHOSPHORYLATION+0.420
- E2F_TARGETS+0.375
- DNA_REPAIR+0.355
- G2M_CHECKPOINT+0.332
- CHOLESTEROL_HOMEOSTASIS+0.330
- UNFOLDED_PROTEIN_RESPONSE+0.300
- WNT_BETA_CATENIN_SIGNALING+0.265
- PROTEIN_SECRETION+0.256
Top 10 suppressed
- ANGIOGENESIS-0.455
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.335
- IL6_JAK_STAT3_SIGNALING-0.295
- KRAS_SIGNALING_DN-0.283
- MYOGENESIS-0.277
- INFLAMMATORY_RESPONSE-0.259
- COAGULATION-0.250
- TNFA_SIGNALING_VIA_NFKB-0.235
- INTERFERON_GAMMA_RESPONSE-0.226
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.211
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 93B9C99A-08DD-4F78-9CF5-C59A01605C9D | — | — | 0.918 |
| 2 | 2C70D7BF-85C4-447B-B0F9-A129D6B49E77 | — | — | 0.912 |
| 3 | C3818F8D-4E33-40AA-8863-E1CD71505597 | — | — | 0.902 |
| 4 | 1C94EA93-563D-4F65-B857-85EF91127874 | — | — | 0.901 |
| 5 | 2CF24C43-7C9D-4395-8C82-5A80361F9980 | — | — | 0.897 |
| 6 | 2482156E-29A8-4B6B-91BD-219EAC9229B5 | — | — | 0.894 |
| 7 | 6EE50ED0-9F0E-4393-B165-257D5C03F221 | — | — | 0.893 |
| 8 | 5F991EDF-3871-4111-9A04-BF6CA02648CA | — | — | 0.884 |
| 9 | 10FB7E59-9D71-4AB9-8D06-9CFD2304D1BC | — | — | 0.882 |
| 10 | 208643FA-0388-44A3-8131-B41AC280107C | — | — | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.588 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.488 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.375 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.355 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.332 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.265 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.256 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.231 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.212 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.212 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.209 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.181 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.179 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.168 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.155 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.127 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.113 | Inavolisib | — uncovered |